Actively Recruiting
Preventing Recurrent Urinary Tract Infections in Women Using Faecal Microbiota Transplantation A Phase 2 and 3 Randomized, Triple-Blind Study
Led by Helsinki University Central Hospital · Updated on 2023-09-22
100
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying faecal microbiota transplantation FMT as a way to prevent recurrent urinary tract infections UTIs caused by either sensitive E. coli or ESBL-E. coli bacteria. This trial is a randomized, triple-blind study sponsored by Helsinki University Central Hospital, aiming to assess FMTs impact on UTI recurrence over time. Participants will be randomly assigned to receive either FMT, which involves transplanting beneficial gut bacteria, or a placebo transplantation using a colored saline solution. The study will compare these groups to evaluate the number and proportion of UTI episodes after treatment, with follow-up lasting up to 12 months and additional long-term monitoring planned for up to five years. During the study, participants will be monitored regularly to track UTI episodes, bacterial strains in urine and feces, gastrointestinal symptoms, depression levels, quality of life, and metabolic profiles. Researchers will also record antibiotic use and assess the eradication of multidrug-resistant bacteria. The total participation time may range from one to five years, with various assessments conducted throughout this period to measure the success and duration of prevention.
CONDITIONS
Brief Title
Faecal Microbiota Transplantation as Means of Preventing Recurrent Urinary Tract Infections
Research Team
S
Sari Pakkanen, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here